Myomo Sees Q3 Revenue $8M-$8.5M Vs $8.35M Est.; FY Revenue $28M-$30M Vs $28.66 Est.; Says 'We Are Continuing Our Efforts To Position The Company To Achieve Revenue Of $10M In Q4 And For Continued Growth In 2025'
Myomo Sees Q3 Revenue $8M-$8.5M Vs $8.35M Est.; FY Revenue $28M-$30M Vs $28.66 Est.; Says 'We Are Continuing Our Efforts To Position The Company To Achieve Revenue Of $10M In Q4 And For Continued Growth In 2025'
Business Outlook
业务展望
"Our backlog entering the third quarter is slightly higher than the backlog we had entering the second quarter. In addition, velocity of revenue recognition is expected to be somewhat higher as we are now recording revenue from Medicare Part B patients at the time of product delivery," added Mr. Gudonis. "As a result, we expect third quarter revenue to be in the range of $8.0 million to $8.5 million. We intend to increase our advertising spending in the second half of 2024 to drive more volume into the top of our patient funnel, which is expected primarily to impact 2025 revenues, We continue to believe our full year revenue expectation of $28 million to $30 million is achievable as the required clinical, reimbursement and manufacturing capacity is in place."
“第三季度进入时,我们的未结订单量略高于第二季度进入时的未结订单量。此外,由于我们现在在产品交付时记录医疗保险部分B患者的收入,因此营业收入确认速度有望略微提高,” 古多尼斯先生补充说。“因此,我们预计第三季度的营业收入将在$800万至$850万之间。我们打算在2024年下半年增加广告支出,以将更多的成交量导入我们患者漏斗的顶部,这主要会影响到2025年的营收收入,我们持续相信我们2021年全年的营业收入预期目标$2800万至$3000万是可以实现的,因为所需的临床、报销和制造能力已经到位。”
"We are continuing our efforts to position the Company to achieve revenue of $10 million in the fourth quarter and for continued growth in 2025," said David Henry, Myomo's chief financial officer. "We continue to believe that operating cash flow breakeven is achievable in the fourth quarter. However, increasing advertising spending to educate prospective patients in the second half of the year may impact achieving this objective."
“我们正在继续努力使公司定位实现第四季度的$1000万营收和2025年持续增长,”Myomo的首席财务官David Henry表示。“我们持续相信,第四季度可以达到经营性现金流平衡点。然而,为了在今年下半年增加广告支出以教育潜在患者,可能会影响实现这个目标。”